Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A rearrange |
Therapy | Ziftomenib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | no benefit | Ziftomenib | Phase I | Actionable | In a Phase Ib trial (KOMET-001), Ziftomenib treatment resulted in an overall response rate of 17% (3/18) and a complete remission or complete remission with partial hematologic recovery rate of 11% (2/18) at the recommended Phase II dose level in acute myeloid leukemia patients harboring KMT2A rearrangements, but enrollment was halted due to increased frequency of differentiation syndrome (PMID: 39362248; NCT04067336). | 39362248 |
PubMed Id | Reference Title | Details |
---|---|---|
(39362248) | Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. | Full reference... |